By Finance Pulse in Transformative —

Eli Lilly Expands While Novo Nordisk Faces Obesity Drug Market Challenges

Eli Lilly's expansion and Novo Nordisk's struggles underscore the volatility in the obesity drug market, impacting healthcare and pharma sectors.

A dynamic illustration depicting contrasting fortunes in the pharma industry: a rising graph for Eli Lilly and a stumbling chart for Novo Nordisk, set against a sleek, modern background.
Eli Lilly Expands While Novo Nordisk Faces Obesity Drug Market Challenges

Eli Lilly's expansion efforts and Novo Nordisk's struggles highlight volatility in the obesity drug market.

Source